Choose ALUNBRIG® (brigatinib) for Proven First-Line CNS Efficacy1

In an ALTA 1L study post hoc subgroup analysis of patients with brain mets at baseline, ALUNBRIG demonstrated durable intracranial responses and extended mPFS vs crizotinib.1,2

ALUNBRIG delivered durable intracranial response1,2

Confirmed Intracranial Overall Response Rates:
Patients with Measurablea Brain Metastases at Baseline1,2

Visualization of intracranial overall response rates, including PR and CR with ALUNBRIG® and PR with crizotinib.
  • In patients with any brain metastases at baseline, ALUNBRIG demonstrated 45% complete intracranial response (n=21/47) vs 4% (n=2/49) with crizotinib2

Study Limitation: ALTA 1L was not powered to detect differences across subgroups.

Brain metastases populationa (post hoc subgroup analysis)

75% Reduction in Risk of Progression or Death vs Crizotinib2,3

Systemic BIRC-assessed PFS in patients with any brain metastases at baseline2,3

Graph of PFS in patients with any brain metastases at baseline. The median PFS with ALUNBRIG® was 24 months, the median PFS with crizotinib was 5.6 months.
  • The INV-assessed median PFS was not reached with ALUNBRIG (95% CI: 18.4, NR) vs 5.9 months (95% CI: 3.7, 7.5) with crizotinib2

Study Limitation: ALTA 1L was not powered to detect differences across subgroups.

ITT population (final analysis with 40.4 months of median follow-up)

ALUNBRIG demonstrated durable intracranial PFS of ~4 years4

Intracranial PFS in the ITT population

Intracranial PFS in the ITT population. Median intracranial PFS with ALUNBRIG® was 44.1 months vs 21.2 months with crizotinib.
  • 3-year intracranial PFS probability in the ITT population (BIRC-assessed): 56% for ALUNBRIG (n=137) vs 38% for crizotinib (n=138)4 
  • In patients with any brain metastases at baseline, the median intracranial PFS was 24.0 months (95% CI: 12.9, 30.8) with ALUNBRIG vs 5.5 months (95% CI: 3.7, 7.5) with crizotinib4 

Intracranial PFS was not part of the statistical testing hierarchy. The clinical relevance of these data is unknown, as only brain lesions were reviewed. Patients were counted as having an event if there was radiologic progression, radiotherapy to the brain, or death.4 

Study Limitation: ALTA 1L was not powered to detect differences across subgroups; results are presented descriptively.

Brain metastases populationa (post hoc subgroup analysis)

57% Reduction in the Risk of Death vs Crizotinib4

OS in Patients with Measurable Brain Metastases at Baseline4

Graph of OS in patients with any brain metastases at baseline, comparing ALUNBRIG® and crizotinib.

Study Limitation: ALTA 1L was not powered to detect differences across subgroups.

  • At a median follow-up of 40.4 months in the ALUNBRIG arm, the 4-year KM-estimated OS rate was 71% (95% CI: 53%, 84%) with ALUNBRIG vs 44% (95% CI: 28%, 59%) with crizotinib4

Real Patient Case Study: Eric

Case study of Eric, a real ALUNBRIG® patient.
Eric’s MRI results revealed a presence of brain metastases. Learn about his treatment journey and results with first-line ALUNBRIG.
DOWNLOAD CASE STUDY

Quality of Life

Explore how ALUNBRIG may impact a patient's quality of life

REVIEW QUALITY OF LIFE

aPatients with brain metastases ≥10 mm in longest diameter at baseline.
bDuration of intracranial response was measured from date of first intracranial response until intracranial disease progression (new lesions, intracranial target lesion diameter growth ≥20% from nadir, or unequivocal progression of intracranial nontarget lesions) or death.

BIRC, blinded independent review committee; CI, confidence interval; CNS, central nervous system; CR, complete response; DOR, duration of response; HR, hazard ratio; INV, investigator; ITT, intent-to-treat; KM, Kaplan- Meier; mPFS, median PFS; NE, not estimable; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response.

IMPORTANT SAFETY INFORMATION, INDICATION, AND USAGE

Expand+